ELMSFORD, NY / ACCESSWIRE / February 4, 2019 / NanoVibronix, Inc, (NASDAQ: NAOV), a medical device company
utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has
launched a new website (www.nanovibronix.com) designed to highlight the advantages of the
Company's proprietary and patented low intensity surface acoustic wave (SAW) devices, including PainShield®, UroShield® and
WoundShield®.
The new site includes a detailed overview of the products, which employ small, disposable transducers that transmit low
frequency, low intensity ultrasound acoustic waves. These devices address a range of clinical applications and help eliminate pain,
repair and regenerate tissue in musculoskeletal / vascular structures, decrease biofilm formation on urinary catheters thus reducing
risk of catheter associated urinary tract infections (CAUTI). The site also features video overviews, patient testimonials,
clinical publications, and recent media featuring the Company's products.
Brian Murphy, Chief Executive Officer of NanoVibronix, commented, "We decided to launch the new site at this time given the
traction we are gaining among potential partners, distributors and consumers. The new site also provides us better platform to
highlight the growing body of clinical evidence validating the efficacy of our technology as we advance our partnering
discussions."
Itai Levinson, Senior Vice President Sales and Marketing, further noted, "We are pleased to announce the launch of our new
corporate website, which includes a much more detailed overview of the advantages of our technology, including each of our
individual products, and reflects our new corporate branding. In particular, the testimonials and video clips provide visitors an
opportunity to see and hear what real people are saying about this technology."
About NanoVibronix
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford,
New York with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary
and patented low intensity surface acoustic wave (SAW) technology. The company's technology allows for the creation of
low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and
bacteria colonization, as well as providing pain relief. The devices can be administered at home, without the assistance of medical
professionals. The company's primary products include PainShieldÔ, UroShieldÔ and WoundShieldÔ. Additional information about the
company is available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing
capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and
other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection
covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S.
and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that
may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking statements as a result of new information, future events or
otherwise.
Investor Contact
David Waldman
Crescendo Communications
naov@crescendo-ir.com
212-671-1021
SOURCE: NanoVibronix, Inc
